Hims & Hers Health, Inc. (HIMS)
Understanding The AI Flywheel At Hims And Hers
Hims & Hers is a subscriber-based online healthcare provider that operates outside of the traditional paradigm. Its AI-native processes and visibility to each patient's full medical journey create a flywheel that's difficult for competitors to replicate. Its moat is further enhanced by its vertical integration and scale.
Hims & Hers: Peptide Ruling A Positive, Operational Good Sense Makes 'Buy' Case (Upgrade)
Hims & Hers Health is upgraded from "Hold" to "Buy," driven by operational discipline and strategic opportunism despite sector volatility. HIMS leverages FDA panel momentum on peptides, expanding into personalized treatments while maintaining a robust telehealth platform and global reach. Management pursues a "best in market" approach to peptide launches, prioritizing clinical rigor, validated supply chains, and data transparency over speed.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.68, moving 3.21% from the previous trading session.
Hims & Hers Health, Inc. (HIMS) Outpaces Stock Market Gains: What You Should Know
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $35.15, moving +2.24% from the previous trading session.
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health: The Market Still Doesn't Get It
FDA staff challenged seven compounded peptides, but Hims & Hers continues expanding internationally and strengthening its core healthcare platform beyond longevity therapies. The $400 million JPMorgan receivables facility improves financial flexibility, supporting GLP-1 expansion without relying on dilutive equity financing. The $1.15 billion Eucalyptus acquisition adds 850,000 customers and approximately $450 million of ARR across eight international markets.
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $36.17, moving 5.51% from the previous trading session.
HIMS Breakout Signals Structural Business Transformation
The stock rebounded from below $14 after a regulatory shock and is now trading above $37 on a diversified growth narrative. Monthly weight-loss subscriber additions exceed one hundred thousand, transforming GLP-1 products into a powerful customer acquisition funnel. Peptides, AI healthcare systems, and international expansion create multi-layered optionality beyond traditional telehealth and pharmacy models.
Hims & Hers stock jumps as Canaccord lifts target price ahead of FDA review
Hims & Hers Health shares (HIMS) surged 9% on Wednesday after Canaccord Genuity raised its price target on the telehealth company, citing improving sales trends, momentum in its weight-loss business, and growing optimism around its peptide opportunity. Canaccord analyst Maria Ripps maintained a Buy rating on the stock while increasing her price target to $40 from $32, implying additional upside from current levels.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health, Inc. (HIMS) Stock Falls Amid Market Uptick: What Investors Need to Know
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $33.39, indicating a -1.62% shift from the previous trading day.
